Effects and tolerability of betahistine in patients with vestibular vertigo: results from the Romanian contingent of the OSVaLD study

References

• BenneckeHPérez-GarriguesHBin SidekDEffects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD studyInt Tinnitus J201016142421609908
   PubMedGoogle Scholar
• Pérez-GarriguesHKuessnerDBeneckeHPatient baseline characteristics in a multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD studyCurr Med Res Opin2007232753276117910803
   PubMed Web of Science ®Google Scholar
• JacobsonGPNewmanCWThe development of the Dizziness Handicap InventoryArch Otolaryngol Head Neck Surg19901164244272317323
   PubMed Web of Science ®Google Scholar
• EnloeLJShieldsRKEvaluation of health-related quality of life in individuals with vestibular disease using disease-specific and general outcome measuresPhys Ther1997778909039291947
   PubMed Web of Science ®Google Scholar
• JarlsäterSMattsonETest of reliability of the dizziness handicap inventory and the activities-specific balance confidence scale for use in SwedenAdv Physiother20035137144
   Google Scholar
• KammerlindASLedinTESkargrenEIOdkvistLMReliability of clinical balance tests and subjective ratings in dizziness and disequilibriumAdv Physiother2005796107
   Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selectionMed Care1992304734831593914
   PubMed Web of Science ®Google Scholar
• HorneyCAWareJEJrRaczekAEThe MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMed Care1993312472638450681
   PubMed Web of Science ®Google Scholar
• McHorneyCAWareJEJrLuJFSherbourneCDThe MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMed Care19943240668277801
   PubMed Web of Science ®Google Scholar
• Saris-BaglamaRNDeweyCJChisholmGBSF Health Outcomes™ Scoring Software User’s GuideLincoln, RI, USAQualityMetric Inc2004
   Google Scholar
• SF-36v2™Scoring SF-36 ScalesLincoln, RI, USAQualityMetric Inc2000
   Google Scholar
• ZigmondASSnaithRPThe Hospital Anxiety and Depression ScaleActa Psychiatr Scand1983673613706880820
   PubMed Web of Science ®Google Scholar
• YardleyLDibbBOsborneGFactors associated with quality of life in Menière’s diseaseClin Otolaryngol Allied Sci20032843644112969347
   PubMed Web of Science ®Google Scholar
• KinneySESandridgeSANewmanCWLong-term effects of Ménière’s disease on hearing and quality of lifeAm J Otol19971867738989954
   PubMedGoogle Scholar
• MichopoulosIDouzenisAKalkavouraCChristodoulouCMichalopoulouPKalemiGHospital Anxiety and Depression Scale (HADS): validation in a Greek general hospital sampleAnn Gen Psychiatry20087418325093
   PubMedGoogle Scholar
• MozaffariehMSacuSBeneschTWedrichAMental health measures of anxiety and depression in patients with retinal detachmentClin Pract Epidemiol Ment Health200731017640389
   PubMedGoogle Scholar
• PallantJFBaileyCMAssessment of the structure of the Hospital Anxiety and Depression Scale in musculoskeletal patientsHealth Qual Life Outcomes200538216364179
   PubMedGoogle Scholar
• FarivarSSCunninghamWEHaysRDCorrelated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.IHealth Qual Life Outcomes200755417825096
   PubMed Web of Science ®Google Scholar
• WhitneySLHudakMTMarchettiGFThe activities-specific balance confidence scale and the Dizziness Handicap Inventory: a comparisonJ Vestib Res1999925325910472037
   PubMed Web of Science ®Google Scholar
• TamberALWilhelmsenKTStrandLIMeasurement properties of the Dizziness Handicap Inventory by cross-sectional and longitudinal designsHealth Qual Life Outcomes2009710120025754
   PubMed Web of Science ®Google Scholar
• NautaJJMeta-analysis of clinical studies with betahistine in Ménière’s disease and vestibular vertigoEur Arch Otorhinolaryngol201427188789723778722
   PubMed Web of Science ®Google Scholar
• ScholtzAWSteindlRBurchardiNBognar-SteinbergIBaumannWComparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority studyClin Drug Investig201232387399
   PubMed Web of Science ®Google Scholar
• MaslovaraSSoldoSBPuksecMBalabanBPenavicIPBenign paroxysmal positional vertigo (BPPV): influence of pharmacotherapy and rehabilitation therapy on patients’ recovery rate and life qualityNeuroRehabilitation20123143544123232168
   PubMed Web of Science ®Google Scholar
• Djelilovic-VranicJAlajbegovicATiric-CamparaMBetahistine or cinnarizine for treatment of Meniere’s diseaseMed Arch20126639639823409520
   PubMedGoogle Scholar
• LepchaAAmalanathanSAugustineAMTyagiAKBalrajAFlunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trialEur Arch Otorhinolaryngol10292013 Epub ahead of print
   Web of Science ®Google Scholar
• GeorgescuMStoianSMogoantăCACiubotaruGVVestibulary rehabilitation – election treatment method for compensating vestibular impairmentRom J Morphol Embryol20125365165622990562
   PubMed Web of Science ®Google Scholar
• BhattacharyyaNBaughRFOrvidasLAmerican Academy of Otolaryngology-Head and Neck Surgery FoundationClinical practice guideline: benign paroxysmal positional vertigoOtolaryngol Head Neck Surg20081395 Suppl 4S47S8118973840
   PubMed Web of Science ®Google Scholar
• AgusSBeneckeHThumCStruppMClinical and demographic features of vertigo: findings from the REVERT RegistryFront Neurol201344823675366
   PubMed Web of Science ®Google Scholar
• HiltonMPinderDThe Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigoCochrane Database Syst Rev20042CD00316215106194
   PubMedGoogle Scholar
• StruppMKremmydaOBrandtTPharmacotherapy of vestibular disorders and nystagmusSemin Neurol20133328629624057832
   PubMed Web of Science ®Google Scholar
• LeziusFAdrionCMansmannUJahnKStruppMHigh-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case seriesEur Arch Otorhinolaryngol20112681237124021626121
   PubMed Web of Science ®Google Scholar
• GauthierSJubyAMorelliLRehelBSchecterRA large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND StudyCurr Med Res Opin2006222251226517076986
   PubMed Web of Science ®Google Scholar
• von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJPThe Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesPLoS One20074e296
   Google Scholar
• AdrionCMansmannUBayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpointBMC Med Res Methodol20121213722962944
   PubMed Web of Science ®Google Scholar
• Jeck-TholeSWagnerWBetahistine: a retrospective synopsis of safety dataDrug Saf2006291049105917061910
   PubMed Web of Science ®Google Scholar